← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

uniQure N.V. (QURE) 10-Year Financial Performance & Capital Metrics

QURE • • Industrial / General
HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases
AboutuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Show more
  • Revenue $27M +71.2%
  • EBITDA -$172M +36.7%
  • Net Income -$240M +22.3%
  • EPS (Diluted) -4.92 +24.0%
  • Gross Margin 32.42% +131.9%
  • EBITDA Margin -632.96% +63.0%
  • Operating Margin -679.58% +61.9%
  • Net Margin -883.35% +54.6%
  • ROE -238.46% -164.3%
  • ROIC -5422.54% -6233.8%
  • Debt/Equity -
  • Interest Coverage -2.89 +57.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 30.1%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y16.89%
5Y30.08%
3Y-62.73%
TTM-44.9%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM1.82%

EPS CAGR

10Y-
5Y-
3Y-
TTM11.49%

ROCE

10Y Avg-26.3%
5Y Avg-13.45%
3Y Avg-30.05%
Latest-28.92%

Peer Comparison

Gene Therapy & Rare Diseases
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
KRYSKrystal Biotech, Inc.8.47B291.9397.31473.02%53.3%17.48%1.41%0.01
BMRNBioMarin Pharmaceutical Inc.10.6B55.2024.9817.97%16.82%8.59%4.48%0.11
SRPTSarepta Therapeutics, Inc.2.25B21.469.1752.97%-11.25%-20.57%0.88
RAREUltragenyx Pharmaceutical Inc.2.33B24.11-3.8329.01%-91.95%-35.88%0.15
DYNDyne Therapeutics, Inc.2.81B17.04-5.06-61.26%0.04
TVTXTravere Therapeutics, Inc.2.6B29.11-7.1360.55%-20.32%-120.36%6.80
BEAMBeam Therapeutics Inc.3.51B34.55-7.54-83.18%-7.44%-42.92%0.22
SLNOSoleno Therapeutics, Inc.2.23B41.51-9.48-79.5%-15.85%0.22

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+10.3M25.1M13.11M11.28M7.28M37.51M524M106.48M15.84M27.12M
Revenue Growth %0.81%1.44%-0.48%-0.14%-0.35%4.15%12.97%-0.8%-0.85%0.71%
Cost of Goods Sold+638.49K72.69M67.41M73.06M0122.4M24.98M3.34M13.63M18.33M
COGS % of Revenue0.06%2.9%5.14%6.47%-3.26%0.05%0.03%0.86%0.68%
Gross Profit+9.67M-47.59M-54.3M-61.78M7.28M-84.89M499.03M103.14M2.21M8.79M
Gross Margin %0.94%-1.9%-4.14%-5.47%1%-2.26%0.95%0.97%0.14%0.32%
Gross Profit Growth %1.26%-5.92%-0.14%-0.14%1.12%-12.66%6.88%-0.79%-0.98%2.97%
Operating Expenses+71.76M97.04M85.06M99.52M128.42M40.54M188.41M246.3M285.09M193.09M
OpEx % of Revenue6.96%3.87%6.49%8.82%17.64%1.08%0.36%2.31%17.99%7.12%
Selling, General & Admin21.12M26M25.04M25.3M33.54M42.58M56.29M54.7M73.08M50.68M
SG&A % of Revenue2.05%1.04%1.91%2.24%4.61%1.14%0.11%0.51%4.61%1.87%
Research & Development51.15M72.51M72.38M74.81M94.74M122.4M143.55M197.59M214.86M143.78M
R&D % of Revenue4.96%2.89%5.52%6.63%13.01%3.26%0.27%1.86%13.56%5.3%
Other Operating Expenses0-283K600K-598K140K-124.44M-11.43M-5.99M-2.86M-1.38M
Operating Income+-74.82M-71.95M-71.96M-88.23M-121.14M-125.43M310.62M-143.16M-282.87M-184.29M
Operating Margin %-7.26%-2.87%-5.49%-7.82%-16.64%-3.34%0.59%-1.34%-17.85%-6.8%
Operating Income Growth %-0.82%0.04%-0%-0.23%-0.37%-0.04%3.48%-1.46%-0.98%0.35%
EBITDA+-69.97M-65.86M-64.41M-81.33M-114.47M-114.78M317.92M-134.62M-270.97M-171.65M
EBITDA Margin %-6.79%-2.62%-4.91%-7.21%-15.72%-3.06%0.61%-1.26%-17.1%-6.33%
EBITDA Growth %-0.78%0.06%0.02%-0.26%-0.41%-0%3.77%-1.42%-1.01%0.37%
D&A (Non-Cash Add-back)4.86M6.09M7.54M6.9M6.67M10.65M7.3M8.54M11.9M12.64M
EBIT-80.69M-70.06M-77.23M-80.91M-120.39M-137.62M311.7M-116.56M-265M-173.39M
Net Interest Income+-2.45M-2.1M-2.36M569K-263K-2.89M-7.31M-11.1M-22M-42.33M
Interest Income121K70K117K2.73M3.55M938K162K609K19.56M21.41M
Interest Expense2.57M2.17M2.48M2.16M3.81M3.83M7.47M11.7M41.56M63.74M
Other Income/Expense-12.11M-283K-8.12M5.16M-3.06M-16.02M22.19M14.9M-23.69M-52.83M
Pretax Income+-78.62M-72.23M-80.59M-83.07M-124.2M-141.44M332.81M-128.26M-306.56M-237.13M
Pretax Margin %-7.63%-2.88%-6.15%-7.36%-17.06%-3.77%0.64%-1.2%-19.35%-8.74%
Income Tax+471.21K1.15M-199K231K0-16.42M3.22M-1.47M1.92M2.43M
Effective Tax Rate %0.99%1.02%1%1%1%0.88%0.99%0.99%1.01%1.01%
Net Income+-78.15M-73.37M-80.39M-83.3M-124.2M-125.02M329.59M-126.79M-308.48M-239.56M
Net Margin %-7.58%-2.92%-6.13%-7.38%-17.06%-3.33%0.63%-1.19%-19.47%-8.83%
Net Income Growth %-0.74%0.06%-0.1%-0.04%-0.49%-0.01%3.64%-1.38%-1.43%0.22%
Net Income (Continuing)-79.27M-73.37M-79.26M-83.3M-124.2M-125.02M329.59M-126.79M-308.48M-239.56M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-3.54-2.93-2.98-2.34-3.20-2.817.04-2.71-6.47-4.92
EPS Growth %-0.35%0.17%-0.02%0.21%-0.37%0.12%3.51%-1.38%-1.39%0.24%
EPS (Basic)-3.54-2.93-2.98-2.34-3.20-2.817.17-2.71-6.47-4.92
Diluted Shares Outstanding22.06M25.04M26.98M35.64M40M44.47M46.84M46.74M47.67M48.65M
Basic Shares Outstanding22.06M25.04M26.98M35.64M40M44.47M45.99M46.74M47.67M48.65M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+229.03M143.95M162.78M236.58M384.21M258.91M628.24M476.77M651.85M390.29M
Cash & Short-Term Investments222.52M132.5M159.37M234.9M377.79M244.93M556.26M352.84M617.89M367.52M
Cash Only222.52M132.5M159.37M234.9M377.79M244.93M556.26M228.01M241.36M158.93M
Short-Term Investments0000000124.83M376.53M208.59M
Accounts Receivable4.13M9.18M1.59M233K947K6.62M58.77M102.38M4.19M5.88M
Days Sales Outstanding146.26133.544.177.5447.4764.3940.94350.9296.679.15
Inventory475.59K996K1.14M1.12M0006.92M12.02M0
Days Inventory Outstanding271.8756.175.58---755.99322.04-
Other Current Assets1.19M1.27M687K329K-3.97M3.02M2.67M2.81M2.65M7.61M
Total Non-Current Assets+35.66M46.32M46.09M37.33M64.42M81.48M180.94M228.19M179.84M166.25M
Property, Plant & Equipment26.04M35.7M34.28M29.18M55.57M58.41M69.08M83.26M75.34M34.07M
Fixed Asset Turnover0.40x0.70x0.38x0.39x0.13x0.64x7.59x1.28x0.21x0.80x
Goodwill483.24K465K530K506K496K542K27.63M25.58M26.38M22.41M
Intangible Assets7.88M8.32M8.8M5.2M5.43M3.36M62.69M58.78M60.48M71.04M
Long-Term Investments1.24M1.83M2.48M2.44M2.93M2.75M039.98M2.18M27.46M
Other Non-Current Assets1.25M1.83M2.48M2.44M2.93M05.9M6.06M3.18M1.4M
Total Assets+264.69M190.26M208.88M273.91M448.63M340.39M809.18M704.96M831.69M556.54M
Asset Turnover0.04x0.13x0.06x0.04x0.02x0.11x0.65x0.15x0.02x0.05x
Asset Growth %1.27%-0.28%0.1%0.31%0.64%-0.24%1.38%-0.13%0.18%-0.33%
Total Current Liabilities+26.65M22.72M19.29M19.97M31.63M27.33M36.76M75.92M73.67M40.05M
Accounts Payable4.06M5.52M2.91M3.79M5.68M3.77M2.5M10.98M6.59M7.23M
Days Payables Outstanding2.32K27.7415.7518.94-11.2536.561.2K176.39143.93
Short-Term Debt5.58M605K1.05M005.52M5.77M8.38M00
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K00
Other Current Liabilities10.3M1.07M2.67M856K08.27M2.87M28.23M45.91M19.12M
Current Ratio8.59x6.34x8.44x11.85x12.15x9.47x17.09x6.28x8.85x9.74x
Quick Ratio8.58x6.29x8.38x11.79x12.15x9.47x17.09x6.19x8.68x9.74x
Cash Conversion Cycle-1.9K110.7734.59-5.83----92.36242.25-
Total Non-Current Liabilities+107.41M103.91M99.64M74.33M93.94M69.16M176.64M153.04M550.34M523.24M
Long-Term Debt14.63M19.63M19.74M35.47M36.06M35.62M100.96M102.79M101.75M51.32M
Capital Lease Obligations000031.13M30.4M28.99M31.72M28.32M11.14M
Deferred Tax Liabilities6.85M6.78M10.41M9.56M0012.91M8.26M7.54M7.04M
Other Non-Current Liabilities85.92M8.67M13.91M10M3.61M3.14M33.78M10.27M412.74M453.73M
Total Liabilities134.06M126.63M118.93M94.3M125.57M96.49M213.4M228.96M624.02M563.29M
Total Debt+21.18M20.24M20.18M35.47M73.06M71.54M135.72M142.89M138.41M66.06M
Net Debt-201.34M-112.26M-139.2M-199.43M-304.73M-173.39M-420.53M-85.12M-102.95M-92.87M
Debt / Equity0.16x0.32x0.22x0.20x0.23x0.29x0.23x0.30x0.67x-
Debt / EBITDA------0.43x---
Net Debt / EBITDA-------1.32x---
Interest Coverage-29.09x-33.12x-29.07x-40.85x-31.80x-32.79x41.56x-12.23x-6.81x-2.89x
Total Equity+130.63M63.63M89.94M179.61M323.06M243.91M595.78M476.01M207.67M-6.75M
Equity Growth %1.49%-0.51%0.41%1%0.8%-0.25%1.44%-0.2%-0.56%-1.03%
Book Value per Share5.922.543.335.048.085.4912.7210.194.36-0.14
Total Shareholders' Equity130.63M63.63M89.94M179.61M323.06M243.91M595.78M476.01M207.67M-6.75M
Common Stock1.33M1.59M1.95M2.3M2.65M2.71M2.8M2.84M2.88M2.94M
Retained Earnings-276.13M-396.06M-467.12M-535.51M-659.71M-784.73M-455.14M-581.93M-890.41M-1.13B
Treasury Stock0000000000
Accumulated OCI28.45M-6.56M39.08M-7.26M-6.69M9.91M-28.86M-58.29M-53.55M-52.8M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+18.78M-72.19M-64.27M-76.04M-98.68M-134.83M287.96M-145.06M-145.93M-182.73M
Operating CF Margin %1.82%-2.88%-4.9%-6.74%-13.55%-3.59%0.55%-1.36%-9.21%-6.74%
Operating CF Growth %1.61%-4.84%0.11%-0.18%-0.3%-0.37%3.14%-1.5%-0.01%-0.25%
Net Income-78.15M-73.37M-80.39M-83.3M-124.2M-125.02M329.59M-126.79M-308.48M-239.56M
Depreciation & Amortization4.86M6.09M8.31M12.41M6.67M10.65M7.3M8.54M11.9M12.64M
Stock-Based Compensation8.34M6.21M10.13M10.71M17.53M21.83M25.64M34.2M35.09M22.26M
Deferred Taxes-523.69K1.15M209K231K0-16.42M3.21M-1.47M1.92M2.43M
Other Non-Cash Items16.06M-1.97M10.12M-9.89M3.42M-19.39M-27.29M-16.16M32.51M23.44M
Working Capital Changes68.19M-10.29M-12.65M-6.2M-2.11M-6.47M-50.48M-43.38M81.12M-3.94M
Change in Receivables-1.72M-5.42M9.71M1.58M-4.77M-6.97M-58.96M-49.08M-1.32M-2.24M
Change in Inventory-256.93K480K382K-382K4.77M00-6.92M-6.74M2.42M
Change in Payables0344K-1.67M1.06M1.65M-2.7M-727K9.24M-4.17M1.52M
Cash from Investing+-9.31M-17.79M-6.15M-4.25M-6.65M-9.48M-67.39M-182.73M-205.69M162.97M
Capital Expenditures-9.41M-17.17M-5.58M-4.25M-6.65M-7.27M-17.44M-17.69M-7.15M-11.69M
CapEx % of Revenue0.91%0.68%0.43%0.38%0.91%0.19%0.03%0.17%0.45%0.43%
Acquisitions----------
Investments----------
Other Investing99.49K-613K-567K-1.86M0-2.21M0000
Cash from Financing+150.4M2.44M90.07M157.96M248.82M7.44M94.86M1.45M362.72M-59.49M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing2.87M2.59M4.78M4.83M6.1M0-1.33M0-7.65M-8.56M
Net Change in Cash----------
Free Cash Flow+9.36M-89.36M-69.85M-80.28M-105.33M-144.31M270.52M-162.75M-153.08M-186.1M
FCF Margin %0.91%-3.56%-5.33%-7.11%-14.47%-3.85%0.52%-1.53%-9.66%-6.86%
FCF Growth %1.17%-10.55%0.22%-0.15%-0.31%-0.37%2.87%-1.6%0.06%-0.22%
FCF per Share0.42-3.57-2.59-2.25-2.63-3.255.78-3.48-3.21-3.83
FCF Conversion (FCF/Net Income)-0.24x0.98x0.80x0.91x0.79x1.08x0.87x1.14x0.47x0.76x
Interest Paid000004.13M6.54M9.25M00
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-85.4%-75.54%-104.69%-61.81%-49.42%-44.1%78.5%-23.66%-90.24%-238.46%
Return on Invested Capital (ROIC)------211.77%189.59%-37.93%-85.61%-5422.54%
Gross Margin93.8%-189.62%-414.3%-547.47%100%-226.28%95.23%96.86%13.98%32.42%
Net Margin-758.41%-292.35%-613.33%-738.25%-1705.82%-333.27%62.9%-119.07%-1947.09%-883.35%
Debt / Equity0.16x0.32x0.22x0.20x0.23x0.29x0.23x0.30x0.67x-
Interest Coverage-29.09x-33.12x-29.07x-40.85x-31.80x-32.79x41.56x-12.23x-6.81x-2.89x
FCF Conversion-0.24x0.98x0.80x0.91x0.79x1.08x0.87x1.14x0.47x0.76x
Revenue Growth80.87%143.57%-47.78%-13.91%-35.48%415.23%1296.82%-79.68%-85.12%71.17%

Revenue by Segment

2018201920202021202220232024
Collaboration revenues---6.6M4.77M2.25M10.87M
Collaboration revenues Growth-----27.81%-52.79%383.20%
License revenues---517.4M100M2.76M10.13M
License revenues Growth-----80.67%-97.24%267.40%
License revenues from related party-------
License revenues from related party Growth-------
License Revenue From Related Party7.53M4.99M32.97M----
License Revenue From Related Party Growth--33.74%560.93%----
License--4.35M----
License Growth-------
Collaborative Revenue From Related Party3.76M2.29M136K----
Collaborative Revenue From Related Party Growth--38.95%-94.07%----
Collaborative Revenue--59K----
Collaborative Revenue Growth-------

Frequently Asked Questions

Growth & Financials

uniQure N.V. (QURE) reported $15.8M in revenue for fiscal year 2024.

uniQure N.V. (QURE) grew revenue by 71.2% over the past year. This is strong growth.

uniQure N.V. (QURE) reported a net loss of $235.1M for fiscal year 2024.

Dividend & Returns

uniQure N.V. (QURE) has a return on equity (ROE) of -238.5%. Negative ROE indicates the company is unprofitable.

uniQure N.V. (QURE) had negative free cash flow of $153.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.